Home » Research Summaries » Search Results

Archives: Research Summaries

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges

Journal: Journal of Neurology; May 8, 2023

Author(s): Abdullah Al-Ani, John J Chen, Fiona Costello

MOGAD: Current understanding and challenges

Fever is a common onset feature of MOG-IgG associated disorders (MOGAD)

Journal: Multiple Sclerosis and Related Disorders; January 11, 2021

Author(s): Alexandre Lampros, Thomas De Broucker, Mickael Bonnan

Could fever be a sign of MOGAD?

Longitudinal Retinal Changes in MOGAD

Journal: Annals of Neurology; September 1, 2022

Author(s): Frederike Cosima Oertel, Elias S Sotirchos, Hanna G Zimmermann, Seyedamirhosein Motamedi, Svenja Specovius, Eva Susanna Asseyer, Claudia Chien, Lawrence Cook, Eleni Vasileiou, Angeliki Filippatou, Peter A Calabresi, Shiv Saidha, Lekha Pandit, Anitha D'Cunha, Olivier Outteryck, Hélène Zéphir, Sean Pittock, Eoin P Flanagan, M Tariq Bhatti, Paulus S Rommer, Gabriel Bsteh, Tobias Zrzavy, Tania Kuempfel, Orhan Aktas, Marius Ringelstein, Philipp Albrecht, Ilya Ayzenberg, Thivya Pakeerathan, Benjamin Knier, Lilian Aly, Nasrin Asgari, Kerstin Soelberg, Romain Marignier, Caroline Froment Tilikete, Alvaro Cobo Calvo, Pablo Villoslada, Bernardo Sanchez-Dalmau, Elena H Martinez-Lapiscina, Sara Llufriu, Ari J Green, Michael R Yeaman, Terry J Smith, Alexander U Brandt, John Chen, Friedemann Paul, Joachim Havla; with the GJCF International Clinical Consortium for NMOSD and the CROCTINO study group

Evaluation of long-term damage to the retina in MOGAD patients

Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide

Journal: Frontiers in Neurology; September 15, 2023

Author(s): Jyh Yung Hor, Kazuo Fujihara

How common is MOGAD worldwide?

Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria

Journal: Neurology Neuroimmunology & Neuroinflammation; November 17, 2023

Author(s): Mirasol Forcadela, Chiara Rocchi, Daniel San Martin, Emily L Gibbons, Daniel Wells, Mark R Woodhall, Patrick J Waters, Saif Huda, Shahd Hamid

Accurate diagnosis of MOGAD relies on the timing of antibody tests

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Journal: Neurology Neuroimmunology & Neuroinflammation; March 26, 2021

Author(s): Romain Marignier, Jeffrey L. Bennett, Ho Jin Kim, Brian G. Weinshenker, Sean J. Pittock, Dean Wingerchuk, Kazuko Fujihara, Friedemann Paul, Gary R. Cutter, Ari J. Green, Orhan Aktas, Hans-Peter Hartung, Fred D. Lublin, Ian M. Williams, Jorn Drappa, Dewei She, Daniel Cimbora, William Rees, Michael Smith, John N. Ratchford, Eliezer Katz, Bruce A.C. Cree

Clinical trial paper on the effect of inebilizumab on disability outcomes in NMOSD

Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Journal: CNS Drugs; September 7, 2022

Author(s): Tina Nie & Hannah A. Blair

A review of inebilizumab treatment in NMOSD

Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study

Journal: Multiple Sclerosis and Related Disorders; August 26, 2021

Author(s): Eoin P. Flanagan a, Michael Levy b, Eliezer Katz c, Daniel Cimbora c, Jorn Drappa c, Maureen A. Mealy c, Dewei She c, Bruce A.C. Cree

Effects of inebilizumab treatment in NMOSD patients who have previously been on rituximab

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

Journal: Multiple Sclerosis Journal; October 1, 2021

Author(s): Mary Rensel, Aram Zabeti, Maureen A Mealy, Daniel Cimbora, Dewei She, Jorn Drappa, Eliezer Katz

Long-term efficacy and safety of inebilizumab in AQP4-positive NMOSD patients over at least 4 years

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Journal: The New England Journal of Medicine; November 28, 2019

Author(s): Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara, Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska-Pniewska, Francesco Patti, Ching-Piao Tsai, Albert Saiz, Hayato Yamazaki, Yuichi Kawata, Padraig Wright, Jerome De Seze

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.